Pittenger & Anderson Inc. Buys 5,421 Shares of ResMed Inc. $RMD

Pittenger & Anderson Inc. lifted its stake in ResMed Inc. (NYSE:RMD) by 5.5% during the 4th quarter, Holdings Channel reports. The firm owned 103,373 shares of the medical equipment provider’s stock after acquiring an additional 5,421 shares during the period. ResMed makes up 1.0% of Pittenger & Anderson Inc.’s holdings, making the stock its 29th biggest holding. Pittenger & Anderson Inc.’s holdings in ResMed were worth $24,899,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its stake in ResMed by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 19,040,440 shares of the medical equipment provider’s stock worth $5,211,940,000 after buying an additional 293,515 shares during the period. Nordea Investment Management AB raised its stake in ResMed by 37.2% during the 4th quarter. Nordea Investment Management AB now owns 1,084,996 shares of the medical equipment provider’s stock worth $262,027,000 after buying an additional 294,124 shares during the period. Dimensional Fund Advisors LP raised its stake in ResMed by 6.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 846,134 shares of the medical equipment provider’s stock worth $231,587,000 after buying an additional 49,540 shares during the period. Caisse de depot et placement du Quebec raised its stake in ResMed by 28.0% during the 3rd quarter. Caisse de depot et placement du Quebec now owns 565,901 shares of the medical equipment provider’s stock worth $154,904,000 after buying an additional 123,781 shares during the period. Finally, Captrust Financial Advisors raised its stake in ResMed by 5.4% during the 3rd quarter. Captrust Financial Advisors now owns 537,623 shares of the medical equipment provider’s stock worth $147,164,000 after buying an additional 27,565 shares during the period. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Transactions at ResMed

In related news, Director Peter C. Farrell sold 2,000 shares of ResMed stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael J. Farrell sold 4,991 shares of ResMed stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $225.50, for a total value of $1,125,470.50. Following the completion of the sale, the chief executive officer directly owned 466,223 shares in the company, valued at approximately $105,133,286.50. This represents a 1.06% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 21,023 shares of company stock worth $5,230,857. 0.65% of the stock is owned by company insiders.

ResMed Price Performance

NYSE:RMD opened at $205.17 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.32 and a current ratio of 3.06. The stock’s 50-day simple moving average is $233.35 and its 200 day simple moving average is $246.50. The company has a market cap of $29.89 billion, a P/E ratio of 19.79, a P/E/G ratio of 1.35 and a beta of 0.85. ResMed Inc. has a 52-week low of $198.64 and a 52-week high of $293.81.

ResMed (NYSE:RMD) last released its earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.79 by $0.07. The business had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $1.42 billion. ResMed had a return on equity of 25.72% and a net margin of 27.44%.ResMed’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.37 earnings per share. As a group, sell-side analysts forecast that ResMed Inc. will post 11.07 EPS for the current fiscal year.

ResMed Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, June 18th. Investors of record on Thursday, May 14th will be given a $0.60 dividend. The ex-dividend date of this dividend is Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. ResMed’s payout ratio is currently 23.74%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Weiss Ratings downgraded ResMed from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday, March 19th. Wells Fargo & Company dropped their price target on ResMed from $270.00 to $227.00 and set an “equal weight” rating on the stock in a research note on Friday. Wall Street Zen cut ResMed from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Robert W. Baird set a $225.00 target price on ResMed in a research report on Friday. Finally, Evercore set a $255.00 target price on ResMed and gave the company an “outperform” rating in a research note on Monday, April 13th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $286.18.

Trending Headlines about ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q3 results beat and margin expansion — ResMed reported revenue up ~11% to ~$1.4B, EPS above consensus, GAAP/non‑GAAP gross margins expanded ~290 bps, strong operating cash flow and $262M returned to shareholders via buybacks/dividends. These fundamentals support longer‑term earnings growth and cash return potential. Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
• Positive Sentiment: Analyst bullish move — Royal Bank of Canada raised its price target to $321 and kept an outperform rating, signaling confidence in ResMed’s growth runway (this raises a sizable upside case). Benzinga
• Positive Sentiment: Dividend maintained and scheduled — Board declared a $0.60 quarterly dividend (ex‑div May 14, payable June 18), modest yield but adds to shareholder returns alongside buybacks.
• Neutral Sentiment: New CFO named — CFO Brett Sandercock will retire and Aaron Bloomer is appointed successor. Management continuity reduces execution risk, though investors will watch cadence of financial reporting under new leadership. ResMed beats quarterly profit estimates, names new CFO
• Neutral Sentiment: Strategic commentary and acquisition talk — Earnings call highlighted continued revenue growth drivers and strategic M&A/portfolio moves; useful context for longer‑term thesis but not immediate catalysts. ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
• Negative Sentiment: Shares slipped after earnings despite the beat — Market reaction was negative post‑release, suggesting investors had higher expectations for guidance, cadence, or near‑term execution; volatility may continue as analysts digest details. RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Mixed analyst reaction — Wells Fargo cut its target to $227 and assigned an equal‑weight rating, reflecting concern about near‑term upside and contributing to selling pressure for investors focused on shorter horizons. Benzinga

About ResMed

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.